Retatrutide Peptide: Benefits, Side Effects, Dosage, and Cost Explained

The investigational triple-agonist behind the highest weight-loss numbers yet reported in the GLP-1 class, and what its research-only status really means.

What Retatrutide Is

Retatrutide (LY3437943) is an investigational peptide built by Eli Lilly to act on three hormone receptors at once. Most weight-loss drugs in this family are a GLP-1 agonist, meaning they copy a single gut hormone that curbs appetite. Retatrutide copies three signals instead: GLP-1, GIP, and glucagon. That third target is what sets it apart, and it is the reason retatrutide has posted the highest average weight loss of any compound in the class.

It is not FDA approved. As of mid-2026 it remains in late-stage human testing, and it cannot be legally prescribed, sold as a medicine, or made up by a compounding pharmacy as a finished drug (Eli Lilly, 2026).

How Retatrutide Works

The three-receptor design is the whole story, so it helps to take each target in turn.

GLP-1 and GIP are the two gut hormones already used by approved drugs. GLP-1 signaling raises satiety (the feeling of being full), slows the stomach, and improves how the body handles insulin. GIP adds to that insulin response and shifts where fat is stored, moving it away from the deep stores packed around the organs.

The new piece is glucagon. Glucagon is usually called insulin's opposite because it tells the liver to release sugar, which sounds wrong for weight loss. But at the balanced doses used in trials, that sugar-raising effect is offset by the other two signals. What remains is a rise in energy expenditure (the calories you burn at rest) and a direct push on the liver to burn its own stored fat (Jastreboff et al., NEJM 2023). In lab tests, retatrutide is actually a weaker match than the body's own hormones at the glucagon and GLP-1 receptors and a stronger match at GIP. It lasts about six days in the body, which is why it is given as a weekly injection under the skin (Sanyal et al., Nature Medicine 2024).

What the Research Shows

Mechanism is promising on paper. The trial results are what moved retatrutide to the front of the field.

In the Phase 2 trial, adults with obesity lost up to 24.2% of their body weight on average after 48 weeks at the highest dose (Jastreboff et al., NEJM 2023). Two Phase 3 trials have since confirmed and pushed those numbers further. TRIUMPH-4, reported in December 2025, showed about 28.7% weight loss at 68 weeks. TRIUMPH-1, reported in May 2026, showed 28.3% weight loss across 2,339 adults over 80 weeks, with nearly half losing at least 30% of their starting weight (Eli Lilly, 2026). Those figures sit close to what bariatric surgery achieves and above the published results for older drugs in the class.

Weight was not the only marker that moved. In people with type 2 diabetes, HbA1c (a three-month average of blood sugar) fell by roughly 2.2%, and most reached the target range (Springer, 2025). A liver substudy was more striking still: at the top dose, liver fat dropped by more than 80% at 24 weeks, which is why retatrutide is being studied for fatty liver disease (Sanyal et al., Nature Medicine 2024). Blood pressure, cholesterol, and waist size improved as well. Because obesity drives conditions like osteoarthritis, sleep apnea, fatty liver, and heart disease, a drug that removes this much weight draws heavy interest across the wider field of peptides for weight loss.

Retatrutide Side Effects and Safety

Strong results always have to be read against the safety record, and here the data is still building.

The most common problems are gut-related: nausea, vomiting, diarrhea, constipation, and stomach discomfort. They tend to rise with the dose and are the main reason trials step the dose up slowly (Jastreboff et al., NEJM 2023). The December 2025 Phase 3 data added a newer signal. About one in five people on the highest dose reported dysesthesia, an odd skin sensitivity or tingling that can feel tender to the touch (Eli Lilly, 2025). As with the rest of the class, gallbladder and pancreas problems are tracked as possible risks, the same GLP-1 safety questions seen across these drugs. The long-term picture will not be settled until the full Phase 3 program reports out.

How Retatrutide Was Dosed in Trials

Because retatrutide is investigational, there is no approved dose, only what researchers have tested.

Trials used a once-weekly injection under the skin, starting low and stepping up over several weeks to blunt the nausea, with the studied range reaching 12 mg per week at the top end (Jastreboff et al., NEJM 2023). That is a description of trial design, not a usage guide. The compound is not approved for people, and nothing here should be read as instructions.

Grey-market vials sold for research ship as a dry powder that has to be reconstituted before it could ever be measured. Turning a target figure into a concentration and the exact units to draw is pure arithmetic, and it belongs in a tool built for it rather than in this article. The retatrutide dosage calculator handles that conversion from vial size and water volume. None of it changes the status: outside a clinical trial, retatrutide is not for human use.

Cost, Sourcing, and the Research-Only Problem

Sourcing is where curiosity most often collides with reality.

Retatrutide is not on pharmacy shelves. The only lawful way to access it is by joining a clinical trial, which you can find through public trial registries (Eli Lilly, 2026). It is sold online anyway as a research chemical, often labeled research-only and marketed with phrases like "buy retatrutide USA." These products are not FDA approved for human use, and the wording matters: knowing what research only actually means is the line between a grey area and a clear one.

Cost is genuinely lower than branded GLP-1 drugs, but the real price is uncertainty. Nothing guarantees the vial holds what the label claims, at the stated purity, free of contaminants. Where people do weigh up research suppliers, third-party testing and a certificate of analysis are the minimum bar. Even then, none of it makes an unapproved compound safe to inject.

How Retatrutide Compares to Semaglutide and Tirzepatide

Retatrutide makes the most sense inside the arc of the drugs that came before it.

Semaglutide, the molecule in Ozempic and Wegovy, hits one receptor and produced roughly 15% weight loss in its main trial. Liraglutide, an earlier once-daily option, did less. Tirzepatide added a second receptor and pushed results into the low twenties. Retatrutide adds the third, glucagon, and sits at the top of the published numbers. The pattern is consistent: each added target has bought more weight loss, though also, so far, more to keep an eye on with side effects. Retatrutide is the newest step, not a finished product, and its place in real care depends on trials that are still running.

Retatrutide Peptide FAQ

References

• Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;389:514-526.
• Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024.
• Eli Lilly and Company. TRIUMPH-4 Phase 3 topline results. December 2025; TRIUMPH-1 Phase 3 topline results. May 2026.
• Triple Agonism Based Therapies for Obesity. Current Cardiovascular Risk Reports (Springer). 2025.